TimeTeller Targets the Timing of Personalised Medicine

German startup TimeTeller is developing tests that measure an individual's circadian rhythm, with a longer-term goal of helping clinicians understand when treatments might work best.

What happened

The company has created a saliva-based test intended to estimate a person's internal biological clock. Its current consumer offering focuses mainly on sleep, lifestyle and wellness insights, while its research programme explores chronotherapy: whether medicines, including some cancer treatments, could be timed differently according to a patient's circadian rhythm. TimeTeller originated from research led by molecular biologist Angela Relógio and has established a reimbursement partnership with German insurer Techniker Krankenkasse for some cancer patients. The company explicitly cautions that its current consumer product does not tell oncology patients when to take medication; drug-specific timing still requires clinical studies.

Why it matters

Precision medicine typically asks which treatment is best for a patient. Circadian medicine introduces another variable: when that treatment should be administered. If validated, timing could potentially improve effectiveness or reduce side effects without changing the medicine itself.

The bigger picture

The concept is scientifically compelling but remains early for many clinical applications. TimeTeller's credibility will depend on prospective trials showing that circadian measurements improve meaningful treatment outcomes.